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 Elevated serum homocysteine, an intermediate of cellular one-carbon metabolism, 
is an independent risk factor for cardiovascular disease (CVD). Folate deficiency increases 
serum homocysteine and may contribute to CVD progression. Vascular smooth muscle cells 
regulate vascular contractility, but also contribute to repair processes in response to vascular 
injury. Nutritional deficiencies, like folate deficiency, are thought to impact on this 
phenotypic plasticity, possibly by epigenetic mechanisms. 
 We have investigated the effect of folate deficiency on vascular smooth muscle cells 
in two cell culture systems representing early and late stages of smooth muscle cells 
differentiation. We find that folate deficiency promotes differentiation towards a more 
contractile phenotype as indicated by increased expression of respective marker genes. 
However, microarray analysis identified markers of striated muscle as the predominant gene 
expression change elicited by folate deficiency. These changes are not merely a reflection of 
cell cycle arrest, as foetal calf serum restriction or iron deficiency do not replicate the gene 
expression changes observed in response to folate deficiency. Folate deficiency only has a 
marginal effect on global DNA methylation. DNA methylation of CpG islands associated with 
genes regulated by folate deficiency remains unaffected. This supports our earlier findings in 
a mouse model system which also did not show any changes in global DNA methylation in 
response to folate and vitamin B6/B12 deficiency. 
 These data suggest that folate deficiency enhances the expression of smooth muscle 
marker gene expression, promotes a shift towards a skeletal muscle phenotype, and does 
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 Hyperhomocysteinemia is a risk factor for all facets of atherosclerotic disease 
including stroke, coronary heart disease and peripheral artery disease [1]. Homocysteine is 
generated as an intermediate of cellular one carbon metabolism. Folate (also known as 
vitamin B9), vitamin B6 and vitamin B12 are all essential components of cellular one carbon 
metabolism, either as substrate or as enzyme co-factors (Fig. 1). Single nucleotide 
polymorphisms or mutations of genes involved in one carbon metabolism are significant 
predictors of vascular disease. In general a lower activity of these enzymes (e.g. MTHFR, 
methionine synthase or cystathionine-b-synthase) is associated with a higher risk of vascular 
disease [2–5].  
 At present it is unclear whether homocysteine acts as a direct promoter of 
cardiovascular disease or whether it is mainly an indicator of low B-vitamin status. 
Numerous studies in animal model systems have assessed the potential mechanisms by 
which homocysteine might directly influence cardiovascular disease risk [6]. These 
experiments typically used diets deficient in folate, vitamin B6 and B12 and rich in 
methionine [7,8] or drinking water enriched with methionine or homocysteine [9]. Some of 
these studies have indeed demonstrated that indicators of vascular disease respond directly 
to serum homocysteine concentrations [10–12]. However, in other studies an increase in 
serum homocysteine was unrelated to the formation of cardiovascular lesions, whereas a 
reduction in serum B-vitamin levels was [7,8,13,14]. This suggests that B-vitamin deficiency 
may promote cardiovascular disease risk by mechanisms other than causing 
hyperhomocysteinemia. This is further supported by findings from several large-scale human 
intervention trials [15,16] using supplementation regimes containing folate, B6 and B12 [16]. 
Typically supplementation of patients with folate and B-vitamins was successful in reducing 
serum homocysteine, but ineffective in preventing cardiovascular mortality [15]. This 
suggests that the major value of homocysteine may be as a marker of B-vitamin deficiency, 
rather than a mechanistic agent in vascular disease development. 
 One alternative hypothesis explaining the role of B-vitamin deficiency in vascular 
disease suggests that a lack of methyl groups available for DNA and histone methylation may 
alter epigenetic gene regulation in the vascular system [17]. Support for this hypothesis 
comes from animal experiments which show that alterations in folate supply in pregnancy 
leads to changes in DNA methylation in “metastable” gene alleles and subsequent changes 
in gene expression and phenotype [18–20]. As these epigenetic mechanisms are important 
for the maintenance of differentiated phenotypes, it has been suggested that a shortage in 
dietary methyl donors may impact on the maintenance of the differentiation status of 
vascular smooth muscle cells and other cell types [21]. Patients with cardiovascular disease, 
who suffered from hyperhomocysteinemia and were given a folate supplement (15 mg oral 
methyltetrahydrofolate a day for 8 weeks) showed an increase in the methylation of 
imprinted genes suggesting that folate supply may influence the DNA methylation status of 
genes [22]. 
 Vascular smooth muscle cells (VSMC) display a flexible phenotype in that they are, 
under normal circumstances, quiescent, contractile and do not synthesize extra-cellular 
matrix or matrix-modifying enzymes [10,23,24]. In the context of vascular injury VSMC 
become mobile, proliferative and secrete extra-cellular matrix proteins, possibly adopting a 
less differentiated phenotype. In VSMC isolated from New Zealand White rabbits a more 
proliferative phenotype is associated with a reduction in global DNA methylation [17,25]. In 
human atherosclerotic lesions global DNA methylation is also decreased relative to normal 
tissue [25]. However, it is unclear, whether this reduction in DNA methylation is a 
prerequisite for increased proliferation. Alternatively, the most proliferative (and by 
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inference, least differentiated) cells in the population of isolated smooth muscle cells may be 
those with a reduced DNA methylation status. 
 We have used two in vitro systems of smooth muscle cell differentiation to 
determine the influence of B-vitamin supply on differentiation status. One model, A404, 
represents early developmental stages of smooth muscle differentiation and one model, 
A7r5, represents a partially differentiated state of vascular smooth muscle cell development. 
We find that folate deficiency impairs cell proliferation, increases homocysteine secretion 
and only leads to marginal changes in global DNA methylation. B-vitamin deficiency 
promotes, rather than prevents, the expression of smooth muscle cell marker genes. 
However, a microarray analysis of folate deficient VSCM suggest a phenotypic shift towards 
a skeletal muscle phenotype. The DNA methylation status of the deficiency responsive genes 
is not affected. This suggests that the methylation of CpG islands in the vicinity of normal 
genes (in contrast to metastable alleles) is not responsive to B-vitamin status. 
 
 
2. Material & Methods 
 
2.1. Cells 
 A404 cells [26],  a gift of Prof Gary Owens, University of Virginia, are derivatives of 
the mouse embryonic carcinoma cell line P19. The cells can be differentiated into several 
lineages, including a smooth muscle cell lineage, in the presence of retinoic acid. The cell line 
also carries a puromycin resistance gene under the control of the smooth muscle specific 
myosin heavy chain 11 (MYH11) promoter. Selection of retinoic acid treated cells in medium 
containing puromycin permits survival of cells which have differentiated towards the smooth 
muscle cell lineage but removes cells which have differentiated into other lineages (e.g. 
neuronal). A404 cells were grown in alpha-MEM medium (Sigma, M8042) supplemented 
with 7.5% of foetal calf serum (Hyclone), 200μg/ml glutamine (Life Technologies) and 
100U/ml penicillin/streptomycin (50U/ml penicillin and 50µg/ml streptomycin; Life 
Technologies) and 200μg/ml hygromycin B (Roche). Cells were split 1:50 every 2 or 3 days 
and used for experiments up to passage 20. Differentiation of cells was induced by the 
addition of 1μM all-trans retinoic acid (Sigma) for 3 days. In some experiments retinoic acid 
treated cells were additionally treated with 0.5μg/ml puromycin (Invivogen) for another 3 
days. Rat A7r5 cells (ECACC catalogue number 86050803) were grown in DMEM (Sigma, D-
6171) supplemented with 10% foetal calf serum (Sigma), 2mM glutamine and 
penicillin/streptomycin at 37°C and 5% CO2 in a humidified incubator.  
 In order to generate folate deficient cells, custom made alpha-MEM and DMEM 
medium was used (BioConcept). The custom-made medium is equivalent to the normal 
medium but does not contain folic acid, vitamin B6 (pyridoxine-HCl; concentration 4μg/ml or 
23μM in DMEM, 1μg/ml or 5.9μM in alpha-MEM), vitamin B12 (cobalamin; absent in DMEM, 
1.36μg/ml or 3.4μM in alpha MEM) and methionine (30mg/l or 200μM in DMEM, 15mg/l or 
100μM in alpha-MEM), which can be added separately. While normal alpha-MEM contains 
both, vitamin B6 and B12, DMEM does not contain vitamin B12. However, sufficient 
amounts of vitamin B12 are contained in foetal calf serum. A reduced folate medium 
(indicated as 10F, containing a folate concentration equivalent to human serum) contained 
10ng/ml of folic acid. A folate deficient medium (indicated as F) contained no folic acid. A 
medium deficient in folic acid and vitamin B6 and B12 is indicated as FB. All media were used 
in conjunction with conventional (i.e. non-dialysed) FCS, which contains 0.6ng/ml of folate 
(as determined by radio-immunoassay). The deficient medium therefore allows for a limited 
level of cell proliferation. Cell numbers were determined by counting in a haemocytometer. 
 For treatment with azacytidine cells were seeded into 6cm dishes in conventional 
medium (DMEM for A7r5 cells, alpha-MEM for A404 cells). 24h later cells the medium was 
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changed to different concentrations of azacytidine (typically 0.1, 1, 5 or 10μM) or control 
medium. 72h later the medium was changed back to control medium. After a further 72h 
cells were counted and genomic DNA was isolated. 
 
2.2. Biochemistry 
 Homocysteine was analysed using isotope dilution GC-MS (gas chromatography and 
mass spectrometry) largely as described [27]. Briefly, medium was harvested from treated 
cells. 100μl of medium was mixed with 50μl of a 50nM C13 labelled homocysteine standard 
solution and 25μl of a 0.1M DTT solution and incubated at room temperature for 20 min. 
After addition of a 2:1 acetonitrile/ethanol solution the reaction was centrifuged at 
13000rpm for 5 min. The supernatant was absorbed to a Strata-X-C spe column 
(Phenomenex) activated with 1ml of methanol. The column was washed consecutively with 
0.5ml of water and 0.5ml of methanol and dried. Homocysteine was eluted into a tube with 
700μl of 5% NH3 in 70% methanol and dried at 90°C under nitrogen. The pellet was treated 
with 10μl of 0.1M DTT and 70μl of 2M NH3 for 30 min. at room temperature and again dried 
under nitrogen at 90°C. The dried material was then resuspended in 50μl of a 1:1 mix of 
MTBSTFA [N-Methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide] and acetonitrile and 
heated to 90°C for 20 min. The tertiarybutyldimethylsilyl (tBDMS) derivative of 
homocysteine was detected by GCMS analysis on a 30m x 0.32mm x 0.25 micron ZB-5MSi 
capillary column. Injections (1μl) were made in the split mode with a 25:1 split. The M-57 
fragment ions at m/z 420 and 421 for unlabelled and 1-C13 labelled homocysteine-tBDMS 
are monitored under electron impact selective ion monitoring conditions (EI-SIM). 
Concentrations of homocysteine were calculated from peak area ratios obtained from EI-SIM 
fitted to a LREG curve generated from standards. Homocysteine concentrations are 
expressed in correlation with cell numbers (as measured by μg of DNA) to evaluate the 
secretion of homocysteine per cell. Typically, homocysteine concentrations in the medium of 
cells grown in full medium are higher (around 10μM) than in the medium of cells grown in 
deficient medium (around 1-5μM). However, the number of cells in the deficient medium is 
substantially lower. 
Folate concentrations were measured using a competitive radio-immuno-assay (RIA) 
assay (MP Biomedicals - SimulTRAC-S radioassay kit Vitamin Folate[125I]; catalogue number: 
06B 254932) following the supplier’s instructions. Briefly, cultured cells were detached from 
plates using Trypsin-EDTA and an aliquot of the cells was counted in a haemocytometer. The 
remaining cells were pelleted by a brief centrifugation and the cell pellet was snap frozen in 
liquid nitrogen. For analysis the cells were thawed by addition of 500μl of standard A (blank), 
resuspended by vortexing and sonicated in an ultrasound water bath for 2 min. Cell culture 
supernatants were measured after diluting 100μl of medium with 400μl of standard A. 1ml 
of tracer solution containing DTT was added and the samples were incubated in a boiling 
water bath for 15min. The samples were then cooled to room temperature in a water bath. 
200μl of antibody beads were added to each sample and incubated at room temperature for 
1 hour in the dark. The beads were subsequently pelleted by centrifugation at 4°C for 10 
min. and the supernatant discarded. The sample tubes were read on a gamma counter 
(Packard Instruments). The readings were correlated with a standard curve (range between: 
1 and 20ng of folate per ml) and the folate concentration was correlated with cell number. 
 
2.3. RNA and quantitative PCR 
 RNA was isolated using the Trizol reagent (Sigma) following the manufacturer's 
protocol (1ml of Trizol per 107 cells). Reverse transcription of RNA was done using MLV 
RNAse(-) reverse transcriptase (Promega) following the manufacturer's recommendations. 
2μg of total RNA was used as template for the cDNA synthesis reaction. A one in 10 dilution 
of the cDNA synthesis reaction was subsequently used as template for quantitative PCR 
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(Applied Biosystems 7500 Fast System). At least three independent experiments were 
carried out for each data point and every sample was measured in triplicate. 
 Quantitative PCR amplifications were carried out with a final primer concentration 
of 0.5μM. Oligonucleotide primers were designed using the Primer BLAST program (NCBI). 
The sequences, annealing temperatures and amplicon sizes of the oligonucleotides used in 
this study are provided in table 1. The quantitative PCR products were evaluated by melting 
point analysis and agarose gel electrophoresis. Amplifications were done at 40 cycles of 15s 
at 95°C, 15s at the indicated annealing temperature and 30s at 72°C. Data were collected at 
the end of each PCR cycle. Standard curves for all genes were generated from serial dilutions 
of a plasmid containing the cDNA for each gene. The crossing points obtained from the 
sample analysis was then correlated with the standard curves to provide a concentration of 
the individual PCR product. Expression of the genes was then correlated with expression of 
the reference genes (β-actin or GAPDH) in the same sample (expressed as pg of gene per pg 
of reference) and expressed as fold change from control treatments. 
 
2.4. Microarray 
 RNA for microarrays was isolated from A7r5 cells grown in medium containing 
2.5ng/ml, 10ng/ml or 100ng/ml of folic acid. The isolation was carried out in cells grown for 
7, 14 or 21 days in the 3 different media (3 time points at 3 concentrations). 2.5ng/ml 
reflects a serum concentration typically seen in folate deficiency; 10ng/ml represents a 
folate sufficient status; 100ng/ml represents serum folate concentrations seen in response 
to folic acid supplement intake. 5 independent samples were analysed for each of the 9 
experimental points. RNA was isolated using the Trizol reagent (Sigma) following the 
manufacturer's protocol, treated with RNAse-free DNAseI (Promega) for 30 min. at 37 C, 
extracted with phenol/chloroform and precipitated with ethanol. The quality of the RNA was 
assessed via the ratio of OD at 260nm and 280nm (only samples with an OD higher than 1.8 
were used) and capillary electrophoresis analysis on Agilent Chips (only RNA with a RIN 
higher than 8 was used). 
 Microarray analysis was done on Affymetrix rat 230-2.0 Genechips by ServiceXS. 
Data from Service XS, in the CEL file format (containing the raw signal intensities) were 
transferred to the MadMax website (https://madmax.bioinformatics.nl) where data was 
analysed using the statistical programming language R [28] and R-libraries offered by the 
Bioconductor project [29]. The data were normalized using Bioconductor and a GCRMA 
method, a Robust Multiarray Analysis with correction for the G:C content of the oligos, and 
then statistically analysed using the Limma package [30], which allowed identification of the 
most differentially expressed genes between different conditions using a nominal p-value 
<0.05 to represent statistical significance. Microarray data were deposited at the NCBI Gene 
Expression Omnibus under accession number GSE125502. 
 
2.5. DNA methylation 
 Genomic DNA isolation was done using the Promega Wizard kit following the 
supplier's instructions. For all DNA methylation analyses reference samples were generated 
which represent methylated and non-methylated DNA. Non-methylated control DNA was 
generated by whole genome amplification of genomic DNA using a Qiagen Repli-G kit. 
Methylated DNA was generated by treating isolated genomic DNA with SssI DNA methyl 
transferase and S-adenosyl methionine (SAM; as substrate) for 1h at 37 C. Additional 
enzyme and additional SAM were added after 30 min. The activity of SssI was monitored 
using bacteriophage lambda DNA as control (suppl. Fig. 6). BstUI restriction digestion of 
lambda DNA (which is not methylated) yields a total of 25 DNA fragments. Treatment of 
lambda DNA with SssI and SAM fully methylates the phage DNA and prevents digestion with 
BstUI (recognition sequence CGCG). Different relative amounts of methylated and non-
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methylated DNA were mixed and assayed by LC-MS to establish a standard curve which 
correlates the percentage of SssI methylated DNA in the mixture and the experimentally 
determined % of methylated cytosine residues (suppl. Fig. 8c). 
 Global DNA methylation was measured using an LC-MS based method developed by 
Friso et al. [31]. Briefly, genomic DNA (1μg per reaction) was sequentially hydrolysed by 
digestion with nuclease P1 (2U per reaction), venom phosphodiesterase I (0.002 U per 
reaction) and alkaline phosphatase (0.5 U per reaction). The resulting hydrolysate was then 
separated by reverse phase HPLC. The 2’deoxycytidine and 5’methyl-2’deoxycytidine peaks 
were detected and quantified with reference to the internal standard 15N3 2’deoxycytidine. 
 Combined bisulfite restriction analysis (COBRA) was carried out as described [32]. 
Briefly, genomic DNA was treated with bisulfite reagent using the EZ DNA methylation kit 
(Zymo Research) and purified using the spin columns provided in the kit. The concentration 
of the converted DNA was measured using a Nanodrop device. 5 ng of bisulfite converted 
DNA was used as template for a PCR amplification using gene specific primer pairs. The 
primer pairs were designed using the Methyl Primer Express software (Applied Biosystems). 
Primer pairs for rat LINE1, rat estrogen receptor alpha exon 1 and rat 14-3-3 sigma (SFN1) 
were taken from the literature [33–35] (table 2). The amplified DNA was purified over a spin 
column (QIAGEN Qiaquick) and 100ng of PCR product were used for a digestion with a 
restriction enzyme whose recognition sequence carries a CG dinucleotide (including BstUI, 
Taq, SfaNI). Aliquots of the restriction reaction were separated on a 10% polyacrylamide gel 
and visualised by ethidium bromide staining. DNA bands were quantified using a Fuji Imaging 
station and the AIDA Imaging software. 
 Pyrosequencing primer combinations (PCR primer pairs and sequencing primer) 
were designed using the Pyromark software package (Qiagen) for the following genes: 
skeletal muscle myosin heavy chain (MYH2), skeletal muscle α-actin (ACTA1), prion protein 
dublet (PRND), thioredoxin interacting protein (TXNIP) and are shown in table 3. Analysis kits 
for the Insig1 (insulin induced gene 1; PM00547638), Id1 (inhibitor of DNA binding 1; 
PM00543697) and Idi1 (isopentenyl-diphosphate delta isomerase; PM00504119) genes were 
purchased from Qiagen. Bisulfite treated DNA was used for the PCR reaction at a 
concentration of 10ng/μl. Pyrosequencing was carried out using the Pyromark Gold Q24 
reagents following the supplier's instructions. 
 
2.6. Protein analysis 
 Cytoplasmic protein extracts for Western blot analysis were prepared as described 
[36]. Briefly, cells were lysed on ice in a buffer containing 25mM KPO4 pH7.8, 8mM MgCl2, 
1mM EDTA, 1% Triton X-100 and 15% glycerol. The extracts were incubated on ice for 5 min. 
and then centrifuged at 4˚C for 1 min. at 10000g. The supernatants were then aliquoted and 
stored at -80˚C. 
 Western blot analyses were carried out after semi-dry transfer of the proteins to a 
nitrocellulose membrane as described [37]. Smooth muscle α-actin (ACTA2, 42kDa) and β-
actin (ACTB, 42kDa) were detected using monoclonal antibodies (Sigma A2547 and A5441, 
respectively) and a horse-radish-peroxidase linked anti-mouse serum (Cell Signalling 
Technologies #7076). All antibodies were used at a dilution of 1:1000. Western blots were 
developed using a chemiluminescent detection kit (Pierce) and the light emission recorded 
on a Fuji Imaging Station. 
 Immunohistochemistry was carried out as previously described [37]. 
 
2.7. Statistical analysis 
 Statistical analysis of datasets was done using one or two-way ANOVA in Microsoft 
Office Excel 2016 and post-hoc analysis and t-tests were carried out Graph-Pad Prism. Error 
bars indicate standard deviations. The number of replicates is indicated for each figure. The 
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significance levels indicated in the figures typically refer to the comparisons between the 
control medium and the modified media. Principal components analysis was done using the 
prcomp function in R applied to scaled data, i.e. using the correlation matrix rather than the 
covariance matrix. Pathway analysis was carried out using the Bioconductor-TopGo 
(https://rdrr.io/bioc/topGO/), DAVID (https://david.ncifcrf.gov/) and ENRICHR 





 Vascular smooth muscle cells surround the endothelium of blood vessels and 
regulate vascular tone in response to exogenous and endogenous signals [23]. They also play 
a key role in vascular repair in response to injury. During this process vascular smooth 
muscle cells switch from a contractile, quiescent phenotype to a proliferative, synthetic 
phenotype in which the cells contribute to the repair process [10]. 
 Cellular one carbon metabolism is fueled by dietary folate and methionine (Fig. 1). 
Increased serum levels of the central metabolite homocysteine have been associated with 
vascular disease including stroke, coronary heart disease and peripheral arterial disease [38]. 
This is particularly obvious in the genetic disease of cystathionine B-synthase deficiency 
which leads to extremely high levels of serum Hcy (up to 100μM compared to a level of 
10μM in healthy individuals) and death as a consequence of vascular disease in early life 
[39]. In addition SNPs in enzymes involved in cellular one carbon metabolism (e.g. MTHFR or 
methionine synthase) are associated with increased risk of atherosclerosis [40]. These 
findings link B-vitamin supply with vascular disease. Therefore, we set out to assess whether 
B-vitamin deficiency affects the switch of vascular smooth muscle cells to a pro-atherogenic 
phenotype. 
 
3.1. Differentiation induces a switch in DNA methyl transferase expression in A404 cells 
 The differentiation capacity of vascular smooth muscle cells cell culture models is 
typically characterised by an increase of smooth muscle cell marker gene expression (e.g. 
MYH11, ACTA2, calponin, SM22/transgelin). To assess the effect of B-vitamin deficiency on 
the process of smooth muscle cell differentiation we first used the A404 model. This cell line 
is derived from mouse PC19 embryonal carcinoma cells and can be differentiated towards a 
smooth muscle cell lineage using retinoic acid. The cells also contain a puromycin marker 
gene under the control of the MYH11 promoter. Therefore cells which have differentiated 
can be enriched by puromycin selection [26]. 
 As a first step we differentiated A404 cells as described and monitored the ensuing 
gene expression changes in smooth muscle cell marker genes ACTA2, SM22, MYH11 and the 
DNA methyl-transferase genes Dnmt1, 3a and 3b. Retinoic acid treatment strongly increases 
the expression of the smooth muscle marker genes ACTA2 (smooth muscle α-actin), SM22 
(transgelin 1) and MYH11 (smooth muscle myosin heavy chain) as measured by quantitative 
PCR (Fig. 2a). This is supported by Western blot analysis and immune-histochemistry analysis 
of ACTA2 protein expression (Fig. 2c and d). At the same time expression of the maintenance 
DNA methyl transferase 1 (Dnmt1) is increased significantly (9 fold) whereas expression of 
the de novo methyl transferase 3b is significantly decreased (Fig. 2b). As expected, the 
relative induction of differentiation process is further enhanced by additional treatment of 
the differentiated cells with puromycin (suppl. Fig. 1). The differentiation process is also 
accompanied by a drastic (more than 1000-fold) reduction in the expression of the stem cell 
marker Oct4 (suppl. Fig. 1c). Retinoic acid treatment of A404 cells for 1, 2 and 3 days reveals 
a gradual increase in smooth muscle marker gene expression over time (suppl. Fig. 1d). 
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These data are consistent with published microarray data analysing the retinoic 
acid/puromycin driven differentiation process (suppl. Fig. 2) [41]. 
 
3.2. Azacytidine treatment promotes smooth muscle cell differentiation in A404 cells  
 Differentiation of A404 cells towards a smooth muscle phenotype is associated with 
Dnmt1 activation. The effect of Dnmt1 activity on the differentiation process was further 
assessed by treating the A404 cells with different concentrations of azacytidine (an inhibitor 
of Dnmt1 activity). Azacytidine treatment was initiated 24h before the 3-day retinoic acid 
treatment. 
 Azacytidine treatment reduces cell viability at concentrations above 0.1μM. But cells 
remain viable even at 10μM, although they divide much more slowly (Fig. 3a). Global DNA 
methylation in A404 cells as measured by liquid chromatography-mass spectrometry (LCMS) 
is not significantly affected by the azacytidine treatment (Fig. 3b). Expression of the smooth 
muscle marker genes α-actin and SM22 is affected by azacytidine treatment at higher 
concentrations. 10μM azacytidine increases expression levels of both marker genes in both, 
the untreated and the retinoic acid treated cells (Fig. 3c and d). Lower concentrations of 
azacytidine also increase expression of α-actin and SM22 in retinoic acid treated A404 cells, 
albeit to a lesser degree (Fig. 3d). Azacytidine has modest effects on the expression of 
Dnmt1 and Dnmt3b at higher concentrations (Fig. 3c, d, e). Combined treatment of cells 
with 10μM azacytidine and retinoic acid increase the expression of the stem cell marker 
Oct4 (Fig. 3e). Treatment of A404 cells with aza-dCTP (rather than azacytidine) shows a 
similar increase in α-actin and SM22 expression in A404 cells in the absence of retinoic acid 
induction (data not shown). Aza-dCTP is more toxic than azacytidine and the effects of 
smooth muscle cell marker expression are seen at a lower concentration (0.5μM aza-dCTP, 
rather than 10μM azacytidine). These data suggest that although Dnmt1 expression in A404 
cells is increased in response to retinoic acid treatment this does not increase global DNA 
methylation and does not appear to be a prerequisite for differentiation. 
 
3.3. Folate deficiency promotes A404 smooth muscle cell differentiation 
 In order to assess the impact of folate, vitamin B6 and vitamin B12 supply on the 
phenotypic plasticity of smooth muscle cells, A404 cells were grown in media containing 
various concentrations of folate, either in the presence of vitamin B6 and B12 or in their 
absence. Cultured cells are typically grown in medium containing a vast excess of folate 
(4000ng/ml). In order to study the effect of folate and B-vitamin deficiency custom made 
medium with a maximum folate supplementation of 1000ng/ml was used. 
 Growth of A404 cells is impaired significantly in folate free medium containing 
vitamins B6 and B12 (Fig. 4a) or devoid of B6 and B12 (Fig. 4b). However, the cells still 
proliferate in this medium, albeit slowly, due to the presence of between 0.5 to 1ng/ml of 
folate in foetal calf serum (typical concentration 0.6ng/ml). The use of dialysed serum 
completely blocks cell proliferation in folate free medium (data not shown). Cellular folate 
stores are severely depleted after an incubation period of 6 days in folate free medium (Fig. 
4c). Therefore, homocysteine secretion per cell is significantly elevated in response to folate 
restriction (homocysteine is an intermediate of cellular one-carbon metabolism which can 
be regenerated to methionine in the presence of folate; Fig. 1). However, overall 
homocysteine concentrations in the medium are higher (around 10μM) in cells grown in 
normal medium compared to cells grown in deficient medium (around 1μM).   No significant 
impact on global DNA methylation can be detected under any of these conditions (Fig. 4e). 
 The expression of the smooth muscle cell marker genes ACTA2, SM22 and MYH11 is 
significantly increased in cells exposed to folate and B-vitamin deficiency, even in the 
absence of retinoic acid (Fig. 4f). The differentiation process induced by retinoic acid 
treatment is significantly enhanced in folate/B-vitamin deficient cells (Fig. 4g). Expression of 
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Dnmt genes and their activation by retinoic acid are not significantly affected by folate/B-
vitamin deficiency (data not shown). These data suggest that B-vitamin deficiency enhances, 
rather than inhibits, the differentiation of A404 cells in response to retinoic acid treatment. 
This conclusion is valid irrespective of the absolute degree of A404 smooth muscle cell 
differentiation. 
 
3.4.  Folate deficiency promotes vascular smooth muscle cell differentiation in A7r5 cells 
 To analyse whether the responses seen in A404 cells, which represent an early stage 
of differentiation also apply to a more differentiated vascular smooth muscle cell line, we 
analysed the bona fide rat vascular smooth muscle cell line A7r5. A7r5 cells respond to 
extended cultivation at confluence with characteristic morphological changes (including cell 
elongation, Fig. 5a), and induction of several smooth muscle marker genes like smooth 
muscle α-actin (ACTA2) and smooth muscle myosin heavy chain (MYH11) (Fig. 5b, c and d). 
A7r5 cell grown under conditions of folate deficiency show a reduction in cell proliferation 
(Fig. 6a and b) even if folate levels are only reduced to the physiological concentration of 
10ng/ml (Fig. 6b and c). Folate deficiency also leads to a decrease in the concentration of 
intracellular folate (Fig. 6d), and an increase in secretion of homocysteine per cell (Fig. 6e). 
The increase of homocysteine secretion is diminished under conditions of additional B6 
deficiency in which cell proliferation and, presumably, overall cell metabolism is attenuated 
(suppl. Fig. 3a). Under conditions of folate deficiency an increase in global DNA methylation 
(as measured by LC-MS) is detectable (Fig. 6f). In conditions of combined folate and vitamin 
B6 deficiency this change in DNA global DNA methylation is not observed (Fig. 6f). This 
change is more pronounced in the presence of vitamin B6 sufficient medium and gradually 
lost in decreasing medium concentrations of B6 (suppl. Fig. 3b). As in A404 cells, the 
expression of the smooth muscle cell marker genes MYH11 and SM22 is increased 
significantly in response to combined folate and B6 deficiency (Fig. 6g). No significant 
changes can be detected in the expression of ACTA2. A trend towards an increase in gene 
expression is found for Dnmt3a (Fig. 6h) which was confirmed in later experiments. Dnmt1 
expression is unchanged and Dnmt3b expression was undetectable by qPCR in A7r5 cells 
(using our experimental set-up). A similar set of responses is also seen if folate deficiency is 
combined with methionine deficiency (suppl. Fig. 4). 
 
3.5. Microarray analysis detects a shift towards skeletal muscle differentiation in response to 
folate deficiency in A7r5 cells 
 To characterise the gene expression changes in response to folate deficiency more 
fully, A7r5 cells were grown in medium containing 100ng/ml, 10ng/ml or 2.5ng/ml of folate 
and the transcriptome was analysed by an Affymetrix microarray. 100ng/ml of folate is 
representative of supra-physiological folate levels only detected in human serum in response 
to the consumption of folate supplements. 10ng/ml folate represents an average 
concentration of human serum folate derived from conventional dietary intake. 2.5ng/ml 
folate represents folate levels found in humans with folate deficiency [42]. 
 RNA was harvested from the cells after 7, 14 and 21 days of cultivation and analysed 
using Affymetrix microarrays. A principal component analysis of the data demonstrates that 
the main differences in overall gene expression manifest themselves at day 14 and day 21, 
whereas fewer significant changes are observed at day 7 (Fig. 7). At day 21 there is 
significant variation between the transcriptome of cells grown at 2.5ng/ml and 100ng/ml, 
whereas the variation between cells grown at 2.5ng/ml and 10ng/ml is less pronounced. This 
is confirmed by Venn diagrams of the gene expression changes (for data with p<0.01 and a 
change bigger than 2-fold; Fig. 8). The top 20 genes regulated by folate availability 
(increased in 2.5ng/ml and increased at 100ng) are shown in table 4. A similar set of gene 
expression changes is found between cells grown at 2.5ng/ml and 10ng/ml, but the 
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amplitude of expression changes is much reduced. E.g. MYH2 expression is increased 11.5-
fold in cells grown in 2.5ng/ml compared to cells grown in 100ng/ml. The fold change is only 
6.5-fold if cell grown in 100 and 10ng/ml are compared (Fig. 9). 
 A pathway analysis was carried out using the TOP-GO, DAVID and Enrichr software 
suites. TOP-GO analysis ([43] evaluating the Gene Ontology-terms of the regulated genes) 
identifies pathways associated with cell division and cell proliferation, and cholesterol 
biosynthesis (GO:0006695) as processes which are significantly regulated by folate 
availability (table 5). These data confirm the key role folate plays as a one-carbon donor for 
DNA synthesis (Fig. 1). 
The effect on cholesterol biosynthesis is also consistent with observations that folate supply 
and lipid metabolism are tightly linked [44–46]. Many of the genes which are significantly 
downregulated in response to folate deficiency (e.g. insulin induced gene 1 [Insig1], 
isopentenyl-diphosphate delta isomerase [Idi1], Steaoryl-CoA desaturase 2 [SCD2]) are 
involved in aspects of lipid and cholesterol biosynthesis [47]. Cholesterol biosynthesis is also 
the signalling pathway most affected by folate deficiency in a WikiPathways analysis (p=1.2 x 
10-10) in the Enrichr software suite (http://amp.pharm.mssm.edu/Enrichr/). The key role of 
folate supply for cell proliferation is supported by the identification of mitotic cell cycle as 
top term in a Reactome 2016 pathway analysis (p value: 3.2 x 10-21) and PLK1 (polo-like 
kinase 1) signalling (a key pathway for mitosis in embryonic cells; p-value 2.4 x 10-12). 
 A Go-term analysis of genes activated by folate deficiency using the DAVID software 
(https://david.ncifcrf.gov/) identifies muscle specific genes (GO:0043292 and related GO-
terms) with the highest enrichment score (p value 2.8 x 10-7). This is consistent with the 
observation that 4 of the 8 genes which are most strongly induced by folate deficiency are 
skeletal muscle specific genes (table 4). Striated muscle contraction is also the most 
significant signalling pathway identified by REACTOME analysis in the ENRICHR software 
suite (suppl. Fig. 5) when a gene list with all genes responsive to folate deficiency (p<0.01; 
fold change >2) is analysed [48,49]. Cardiac myopathy is the disease network most closely 
associated with this gene list (suppl. Fig. 5b). Other genes which are activated by folate 
deficiency include prion protein dublet (Prnd) and inhibitor of DNA binding 1 (Id1). Both of 
these genes are associated with pro-angiogenic function [50–53]. Consistent with this 
observation the HIF-1a transcription factor network is the most significant NCI-Nature gene 
network activated in response to folate deficiency (ENRICHR) (suppl. Fig. 5a). Expression of 
several smooth muscle marker genes (including MYH11, ACTA2, SM22, MYL6L) and other 
muscle specific marker genes (including the transcription factors serum response factor and 
myocardin) are increased significantly (p<0.001), albeit by a small margin (up to around 1.5-
fold) in response to 2.5ng/ml folate treatment (data not shown). This suggests that the 
higher induction rates seen in deficient medium (0.6ng/ml, Fig. 6g) are elicited by the lower 
concentration of folate in the medium. Genes encoding enzymes of the cellular one carbon 
metabolism are only marginally changed by low folate. The biggest significant changes are 
found for dihydrofolate reductase (DHFR, down-regulated by 1.9-fold in 2.5ng/ml vs 
100ng/ml of folate, p<0.001) and methylene-tetrahydrofolate dehydrogenase (MTHFD2, up-
regulated by 2-fold in 2.5ng/ml vs 100ng/ml of folate, p<0.001). 
 Taken together the microarray results confirm that smooth muscle cell markers are 
increased in response to folate deficiency, but that genes associated with a skeletal muscle 
phenotype are increased more strongly, together with genes associated with angiogenesis. 
 
3.6. Folate deficiency induced gene expression changes are not caused by cell cycle arrest  
 The expression of the 8 most responsive genes (4 most highly activated in response 
to high folate and 4 most highly activated in response to low folate) was confirmed using 
quantitative PCR (data not shown). To assess whether the changes in gene expression were 
merely due to cell cycle arrest in response to folate deficiency, A7r5 cells were exposed to 2 
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other stimuli known to reduce cell proliferation. The cells were grown in medium containing 
0.5% FCS or supplemented with 0.01μM of the iron chelator deferoxamine (DFO). Both 
treatments significantly reduce cell proliferation (Fig. 10a and b) similar to folate restriction 
(Fig. 6c). Expression of 7 genes regulated by folate deficiency (4 downregulated by low 
folate: TXNIP, IDI1, ID1 and INSIG1, 3 upregulated by folate deficiency: MYH2, ACTA1, and 
PRND) was measured in response to FCS reduction and iron deficiency using quantitative 
PCR. Expression of IDI1 and ID1 was significantly reduced in response to FCS reduction (as 
under conditions of folate deficiency) and INSIG1 expression was significantly reduced in 
response to Fe deficiency (albeit much less than in response to F deficiency). In the case of 
TXNIP1, MYH2, ACTA1 and PRND only folate deficiency elicited the characteristic gene 
expression changes, whereas iron deficiency and low FCS did not. This suggests that most of 
the gene expression changes observed in the microarray are specific to folate deficiency 
rather than a reflection of cell cycle arrest. During this analysis it was also found that 
expression of Dnmt3a was increased in response to folate deficiency (but not iron deficiency 
or low serum, Fig. 10d) confirming the trend seen in Fig. 6h. 
 
3.7. Folate deficiency induced gene expression changes are not associated with changes in 
gene specific DNA methylation 
 To assess whether the observed gene expression changes are correlated with gene 
specific changes in DNA methylation, A7r5 DNA derived from folate deficient and iron 
deficient cells and cells grown in low serum (0.5%) were analysed using combined bisulfite 
restriction analysis (COBRA) and pyrosequencing. Reference points for non-methylated DNA 
and methylated DNA were established by whole genome amplification and DNA 
methyltransferase SssI treatment, respectively, and used to establish standard curves for 
methylation frequency in all experiments (suppl. Fig. 6a). 
 Whole genome amplified A7r5 DNA only shows 0.2% of all cytosine residues being 
methylated when analysed by LC-MS [31] (suppl. Fig. 6d). In contrast in untreated A7r5 DNA 
3.1% of all cytosine residues are methylated. Treatment of naïve A7r5 DNA with SssI and 
SAM increases the frequency of methylated cytosine residues to 5% (suppl. Fig. 6d). In 
contrast whole genome amplified DNA treated with SssI only contains 1.2% of cytosine 
residues in a methylated state. This suggests that SssI treatment has limited efficiency on 
non-methylated genomic DNA (suppl. Fig. 6d). Genomic DNA derived from azacytidine 
treated A7r5 cells show a progressive global demethylation as assessed by LC-MS (suppl. Fig. 
7). 
 Gene specific methylation of LINE1 and estrogen receptor alpha was measured in 
genomic DNA derived from folate deficient (and control) A7r5 cells using COBRA (Fig. 11 and 
suppl. Fig. 8 and 9). Methylation of LINE1 was marginally increased in response to folate 
deficiency (Fig. 11e and suppl. Fig. 8c and d). It remained unchanged in response to cell 
cycle arrest inducing treatments of A7r5 cells in 0.5% FCS and DFO treatment (Fig. 11f). 
Similarly, methylation of ERα was marginally increased in response to folate deficiency 
(suppl. Fig. 9d). No significant change in DNA methylation was found for the tumour 
suppressor gene 14-3-3 sigma (SFN, data not shown) [35]. These marginal DNA methylation 
changes contrast with a control experiment in which we could find a strong methylation of 
the CMV promoter in A404 cells compared with HEK293 cells, which correlates with the 
expression rates of a CMV promoter driven nuclear GFP protein (suppl. Fig. 10). Methylation 
of a BstUI site in the Prnd gene, which is strongly activated in response to folate deficiency, 
is significantly decreased in response to folate deficiency, but not in response to reduced 
serum and iron deficiency (DFO treatment) (Fig. 12). 
  To get a more comprehensive overview over gene specific methylation in A7r5 cells 
in response to folate deficiency, iron deficiency and restricted FCS, 7 of the genes strongly 
regulated by folate deficiency were assessed for gene specific DNA methylation using 
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pyrosequencing. CpG islands were identified using the Methyl Primer Express software 
(Applied Biosystems) and confirmed using the CpG finder software. All 7 genes carry a CpG 
island in the vicinity of the gene (suppl. Fig. 11). Pyrosequencing assays for these areas were 
developed using the pyromark software (for Myh2, Acta1, Prnd, Txnip) or purchased as kits 
from QIAGEN (for Id1, Idi1 and Insig1). The overall methylation rate of the gene sequences is 
highly variable ranging from 5% for ID1 to 90% for PRND. This may reflect the position of the 
CpG islands relative to the transcriptional start site (table 3) which is a known determinant 
of genome methylation [54]. The results do not show a significant change in gene specific 
DNA methylation for any of the genes in response to the different treatments (Fig. 13). 
Control reactions using mixtures of whole genome amplified DNA and SssI treated DNA 
demonstrate that all sites tested are amenable to the presence and absence of DNA 
methylation (as shown for the Prnd gene in Fig. 13g). In contrast, a significant (albeit small) 
decrease in DNA methylation was detected in the Prnd gene in response to azacytidine 
treatment (suppl. Fig. 12). Taken together with the change in DNA methylation found in the 
COBRA analysis, this suggests that the Prnd gene may be most susceptible to gene regulation 





 We have analysed the effects of folate deficiency on the phenotypic plasticity of 
vascular smooth muscle cells. Our results demonstrate, firstly, that folate deficiency induces 
significant changes in global gene expression patterns indicating that the cells adopt a more 
contractile phenotype. Secondly, the overall expression pattern suggests a trans-
differentiation towards a skeletal muscle phenotype. Thirdly, folate deficiency mediated 
alterations of cellular one-carbon metabolism do not induce DNA methylation changes in 
CpG islands associated with folate responsive genes. 
Folate deficiency is associated with several disease phenotypes. The most important 
of these is neural tube defects [55,56] which has led to the introduction of fortification of 
flour with folic acid in some countries [57]. The caveat to this approach is the promotion of 
cell proliferation which can have a small but measurable cancer promoting effect [58]. This is 
not surprising as many cancer drugs (e.g. methotrexate; see Fig. 1) act as anti-folates 
interfering with folate-supported DNA synthesis. Another well characterised disease 
outcome of folate deficiency is colon cancer which has been documented in animal studies 
and epidemiological observations in human populations [59]. Finally, folate deficiency (and 
one of its physiological outcomes, increased serum homocysteine levels) is associated with 
an increased risk of cardiovascular disease [60,61]. The mechanisms by which B-vitamin 
deficiency impacts on CVD risk, however, are unclear. 
 
Numerous studies have investigated potential direct effects of homocysteine on 
vascular health. Several mechanistic explanations have been put forward including a 
promotion of inflammation, an increased proliferation of VSMC in the neointima, a toxic 
effect on the vascular endothelium, and cell signalling alterations [62]. Some studies in 
model systems seemed to support a mechanistic role for homocysteine in cardiovascular 
disease progression by promoting VSCM proliferation [11]. However other studies (including 
our own) failed to establish a conclusive link between serum homocysteine concentrations 
and vascular disease progression [7,8,13]. Specifically, our data demonstrate that plaque 
formation is not correlated with serum homocysteine levels. Under conditions of combined 
folate and B-vitamin deficiency serum homocysteine levels of around 50μM were detected, 
whereas folate deficiency alone only increased serum homocysteine to 15μM. In contrast, 
significant increases in plaque formation were detected in folate deficient, but not in 
B-vitamin mediated gene regulation in vascular smooth muscle cells  
14 
 
combined folate/B-vitamin deficient mice [8]. This is supported by another rodent model 
system, which specifically demonstrated that provision of high methionine seems to be the 
predominant driver of vascular disease and not high homocysteine levels [13]. These data 
argue against a direct link of serum homocysteine levels with the extent of vascular plaque 
formation. 
Moreover, the finding that B-vitamin supplementation in cardiovascular patients 
reduces serum homocysteine, but appears to be of no clinical benefit has led to the 
suggestion that homocysteine may be a marker for B-vitamin deficiency, rather than an 
active agent in vascular disease progression [15,16]. These findings may be explained in two 
ways. Firstly, homocysteine may have no further effect on disease progression, once overt 
cardiovascular disease is present. Alternatively, homocysteine lowering may only be clinically 
effective in the small group of patients which suffer from severe hyperhomocysteinemia (i.e. 
serum homocysteine levels of higher than 100μM; incidentally this is the concentration 
which is typically used in rodent and in vitro models of hyperhomocysteinemia) [62]. 
Therefore, other mechanistic links between B-vitamin deficiency and cardiovascular disease 
risk are being considered. 
 
 Hiltunen et al. observed a reduction in global DNA methylation of vascular smooth 
muscle cells in association with cardiovascular disease in a mouse/rat model [25,63]. This led 
to the hypothesis that B-vitamin deficiency may exert its effect on cardiovascular disease via 
epigenetic mechanism like DNA methylation or histone methylation. A potential link 
between folate supply, DNA methylation, and gene expression has been demonstrated e.g. 
for the agouti mouse model and related “metastable” alleles [64]. We have therefore 
studied the effects of folate, vitamins B6 and B12, and methionine deficiency in two 
complementary cell culture models representing early and late differentiation stages of 
vascular smooth muscle cells.  
 
 Our results allow two major conclusions. Firstly, folate deficiency does not prevent 
the establishment or maintenance of a differentiated vascular smooth muscle phenotype. In 
fact, the expression of smooth muscle cell marker genes is increased in response to folate 
deficiency in both, A404 and A7r5 cells. However, the microarray analysis of A7r5 cells 
suggests a shift of overall gene expression towards a skeletal muscle phenotype. Trans-
differentiation on A7r5 cells into skeletal muscle has been observed before as a spontaneous 
outcome of cultivation but was only characterised by expression of two skeletal muscle 
proteins [65]. Our results suggest that an exogenous stressor like folate deficiency can 
promote this process. In addition, several genes involved in tissue repair are also activated in 
response to folate deficiency, while genes involved in cholesterol and lipid metabolism are 
downregulated. This is also reflected for the overall transcriptome by pathway analyses. The 
close link between B-vitamin/one carbon metabolism and lipid metabolism is well 
characterised and supports the findings of other researchers [44–46]. Trans-differentiation 
of VSMC in vivo has been documented [66,67] but is controversial [68,69]. The most relevant 
trans-differentiation processes observed in vivo appear to be towards an osteogenic and 
macrophage (rather than a skeletal muscle) lineage [66,67].  
 We have previously studied the effects of folate and vitamin B6 and B12 deficiency 
in the arterial tissue of folate deficient apoE-/- mice using proteomics [8,70]. Some of the 
changes seen in that analysis are also reflected in the A7r5 cells. E.g. the transferrin 
receptor, the electron-transfer flavoprotein, lactate dehydrogenase, glutathione-S-
transferase mu1, several fibrinogen polypeptides are all significantly upregulated in 
conditions of folate deficiency in both analysis systems. The fact that the major changes seen 
in A7r5 cells are not seen in the whole aorta is presumably due to the different sensitivities 
of the two analyses (microarray vs proteomics, the latter only revealing changes in highly 
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expressed proteins) and the modest contribution of smooth muscle cells to the overall tissue 
composition of a complete aorta. 
 
 The second conclusion from the data presented is that changes in gene expression 
are not correlated with significant changes in DNA methylation of CpG islands associated 
with genes regulated by folate supply. This is in accordance with recent findings by McKay et 
al. who found that gene expression and DNA methylation changes in the liver of folate 
deficient mice were not correlated for most genes [71]. In addition, Wang et al. investigated 
the role of DNA methylation in a model of neural tube defects, and found that the 
expression of very few genes was changed as a consequence of DNA methylation changes 
[72]. In contrast, Leclerc et al. found small but significant increases in the methylation of CpG 
islands associated with tumour suppressor genes in colon tumours induced by folate 
deficiency in C57B/6 mice [73]. However, even in that case the DNA methylation changes 
detected (by pyrosequencing) were in the range of a few percent; similar to the amplitude of 
changes we detect in some of the assays, especially for the Prnd gene. The available data 
suggest that while the methylation status of some genes is sensitive to environmental 
changes (like folate supply) for most genes no significant methylation changes are found. In 
order to conclusively assess the specific effect of environmental changes on DNA 
methylation a whole genome sequencing of bisulfite converted DNA would be necessary. 
 Recent technological advances have enabled the site directed modification of DNA 
methylation using fusion proteins of Cas9 with Dnmt3a or Tet1 [74–76] in which the 
methylating or demethylating activities are targeted to sites specified by guide RNAs 
interacting with Cas9. While these experiments clearly demonstrate a link between the 
methylation of target genes with their expression, it is possible that these effects only apply 
to a subset of genes. Our data also show profound impacts of DNA methylation on the 
expression of a CMV-GFP transgene stably inserted in HEK293 cells and A404 cells. Taken 
together these data suggest that a simple correlation between gene specific DNA 
methylation changes resulting in altered gene expression, as is the case for metastable 
alleles, is not generally applicable. Alternatively, DNA methylation changes in one genomic 
location may have long range effects on chromosome architecture resulting in changes of 
expression of distant genes with consequent changes in biological phenotypes. 
 The results in this study also raise the question as to how important folate supply is 
for DNA methylation. It is probable that DNA methylation of genes is mainly malleable 
during early stages of development (as reflected in the A404 cells). Effects of early life 
nutrition on cardiovascular disease risk have indeed been demonstrated [77]. We only 
detected small changes in global or gene specific DNA methylation in both vascular smooth 
muscle cell lines in response to folate deficiency, reflecting our findings in mice [8]. Human 
studies have demonstrated that folate and B-vitamin supply in utero can have differing 
effects on the methylation of different imprinted genes [78,79]. In addition, direct analysis of 
gene expression correlated with these methylation changes is restricted as very few tissues 
which are accessible for such studies in humans (mainly lymphocytes). 
DNA methylation enzymes compete for methyl groups with other cellular processes 
like DNA synthesis [80]. In tumour cells an increased requirement for de novo nucleotide 
synthesis can therefore decrease overall levels of DNA methylation. However, even a 
dramatic increase in the DNA de novo synthesis rate of 36% (e.g. in tumour cells) only 
reduces the DNA methylation rate by 0.5% [81] suggesting that DNA methylation is not 
particularly responsive to one carbon unit supply. In addition, histone methylation, another 
mechanism of epigenetic gene control, may also provide a target for gene regulatory effects 
of folate deficiency. It has been suggested that THF (derived from dietary folate) is required 
to protect lysine demethylase enzymes from the formaldehyde generated as a consequence 
of histone demethylation [82]. Folate deficiency may therefore impair histone 
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demethylation thereby impacting on gene regulation. B-vitamin deficiency may also affect 
cardiovascular disease risk indirectly via other processes, including DNA repair, micro RNA 
stress responses, inflammation and energy sensors, like mTOR [83–86] either with or 





Taken together the data shown in here demonstrate that folate deficiency promotes 
a contractile phenotype in vascular smooth muscle cells, combined with a trans-
differentiation towards a skeletal muscle gene expression profile. These expression changes 
are not accompanied by altered DNA methylation of the regulated genes. The data also 
clearly show that a simple correlation of gene specific DNA methylation changes and altered 
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Table 1: Oligonucleotides used for quantitative PCR. Primer sequences, annealing 
temperatures and expected product sizes are given. 
 
Table 2: Oligonucleotides used for COBRA analyses. 
 
Table 3: Oligonucleotides used for pyrosequencing analyses and gene sequences analysed. 
 
Table 4: Top 20 gene expression changes in response to folate deficiency. Fold change of 
gene expression between A7r5 cells grown in in folate sufficient (100ng/ml) and folate 
deficient (2.5ng/ml) medium 
 
Table 5: TOP-GO pathway analysis of transcriptome changes in response to folate deficiency. 
elimKS here gives the p-values from topGO specific Kolmogorov-Smirnov Test with 
elimination of genes of significant GO-terms in parent terms. 
 
Figure 1: Schematic representation of cellular one carbon metabolism. Relevant enzymes are 
shown: methylene tetrahydrofolate reductase (MTHFR), methionine synthase (MS), 
cystathionine-B-synthase (CBS), di-hydrofolate reductase (DHFR), betaine-homocysteine S-
methyltransferase (BHMT). Enyzmes dependent on B-vitamins are indicated [B6], [B12]. 
Dietary folate is a precursor for both, DNA synthesis and DNA methylation. Methotrexate is a 
classic example of an “anti-folate” used in cancer therapy. It is a highly effective competitive 
inhibitor of DHFR. 
 
Figure 2: Analysis of smooth muscle marker and Dnmt gene expression in A404 cells. A404 
cells were treated with 1μM all-trans retinoic acid (dissolved in DMSO; stock solution 1mM) 
or equivalent concentration of solvent for 3 days. RNA was isolated, reverse transcribed and 
analysed by quantitative real time PCR. Expression of the smooth muscle α-actin (ACTA2), 
SM22, myosin heavy chain (MYH11), Dnmt1, Dnmt3a and Dnmt3b genes was measured and 
correlated with expression of the reference gene GAPDH. Panel A: Fold induction of the 
smooth muscle cell marker genes ACTA2, SM22 and MYH11 in A404 cells treated with 
retinoic acid supplemented medium relative to control medium. Panel B: Fold induction of 
the DNA methyl-transferase genes Dnmt1, 3a and 3b in A404 cells treated with retinoic acid 
supplemented medium relative to control medium. Panel C: Western blot analysis of 
cytoplasmic extracts from A404 cells treated with retinoic acid supplemented medium 
([+]RA) and control medium ([-]RA). Smooth muscle α-actin (ACTA2) and β-actin (ACTB) were 
detected using specific monoclonal antibodies. Statistical analysis was done by ANOVA (n=4). 
p<0.05: *, p<0.01: **, p< 0,001: ***. Panel D: Immunohistochemistry analysis of ACTA2 
protein expression in untreated ([-]RA [-]puro), retinoic acid treated ([+]RA [-]puro) and 
retinoic acid and puromycin treated ([+]RA [+]puro) A404 cells. 
 
Supplementary Figure 1: Changes in gene expression in response to retinoic acid treatment 
and combined retinoic acid/puromycin treatment in A404 cells. Panel A: Expression of 
smooth muscle marker genes smooth muscle α-actin (ACTA2), transgelin 1 (SM22) and 
smooth muscle myosin heavy chain (MYH11) in response to treatment with retinoic acid for 
3 days (d3 [+]RA) and after treatment with retinoic acid for 3 days and treatment with 
puromycin for another 3 days (d6 [+]RA). Data are shown as fold change in expression from 
untreated cells at day 3 (d3 [-]RA). Expression data were correlated with the expression of 
the reference gene GAPDH. Panel B: Expression of ACTA2, SM22 and MYH11 correlated with 
the reference gene β-actin. Panel C: Expression of Dnmt1, 3a and 3b and Oct4 in response to 
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treatment with retinoic acid for 3 days (d3 [+]RA) and after treatment with retinoic acid for 3 
days and treatment with puromycin for another 3 days (d6 [+]RA). Data are shown as fold 
change in expression from untreated cells at day 3 (d3 [-]RA). Expression data were 
correlated with the expression of the reference gene GAPDH. Panel D: Expression of ACTA2, 
SM22 and MYH11 in response to retinoic acid treatment for 1, 2, and 3 days. Data are shown 
as fold change in expression from untreated cells at day 3 (d3 [-]RA). Expression data were 
correlated with the expression of the reference gene GAPDH.  
 
Supplementary Figure 2: Expression data for the smooth muscle marker genes ACTA2 (panel 
A) and SM22 (panel B), the differentiation marker Oct4 (panel C) and the Dnmt1, 3a and 3b 
genes (panels D to F) in response to treatment of A404 cells with retinoic acid for 48h or 96h 
or treatment with retinoic acid for 96h with subsequent puromycin selection (96h-P). Data 
are derived from Spin et al. 2010 via the Gene Expression Omnibus at the NCBI. 3 different 
probe sets, representing variations in the expression of splice variants are shown for 
Dnmt3a.  
 
Figure 3: Impact of azacytidine treatment on cell proliferation and global DNA methylation. 
A404 cells were grown in medium containing 0.1μM, 1μM or 10μM of azacytidine or in 
normal medium for 6 days. 104 cells were seeded, and cell numbers were recorded on day 3 
and 6. Genomic DNA was isolated at the end of the incubation and analysed by LC-MS. Panel 
A: Cell proliferation of cells grown in the different media. The number of cells was 
determined by trypan blue staining at the indicated time points using a haemocytometer 
(n=6). Panel B: Global DNA methylation. The percentage of methylated cytosine residues is 
shown (n=3). Panels C-E: Analysis of gene expression in azacytidine treated A404 cells. A404 
cells were treated with azacytidine for 24h and then induced with all-trans retinoic acid or 
equivalent concentration of solvent for 3 days in the continued presence of azacytidine. RNA 
was isolated, reverse transcribed and analysed by quantitative real time PCR. Expression of 
the smooth muscle α-actin (ACTA2), SM22, Dnmt1, Dnmt3b and Oct4 genes was measured 
and correlated with expression of the reference gene GAPDH in A404 cells treated with 
different concentrations of azacytidine. Expression is show as fold change from control cells 
(not treated with azacytidine). Panel C: Fold induction of the ACTA2, SM22, Dnmt1, Dnmt3b 
and Oct4 genes in response to azacytidine treatment without retinoic acid. Panel D: Fold 
induction of the ACTA2, SM22 and Dnmt1 genes in response to combined retinoic acid and 
azacytidine treatment. Panel E: Expression of the Dnmt3b and Oct4 genes in response to 
combined retinoic acid and azacytidine treatment. Statistical analysis was done by ANOVA 
(n=3). p<0.05: *, p<0.01: **, p< 0,001: ***.  
 
Figure 4. Impact of folate and vitamin B6/12 deficiency on A404 cells. Panels A-B: 
Proliferation of A404 cells in different cell culture media as determined by trypan blue 
staining at the indicated time points using a haemocytometer. Cells were grown in medium 
containing 100, 100, 10 or 0ng/ml of folate either in the presence of B-vitamins (Panel A) or 
in their absence (Panel B). The folate deficient medium (0ng/ml) contains residual folate 
derived from foetal calf serum at a final folate concentration of 0.6ng/ml. 2*104 A404 cells 
were seeded into 6 cm dishes and grown for 7 days. Cells were counted after 3, 5, and 7 
days. The average of 4 independent experiments is shown. Panel C: Intracellular folate 
concentration in cells grown in folate deficient (F; 0ng/ml) or folate and B-vitamin deficient 
(FB) media. Concentrations determined by radio-immunoassay are shown as pg folate per 
104 cells. Panel D: Homocysteine concentrations in cell culture medium as measured using a 
GC-MS method. Concentrations in nM per μg of DNA (isolated from the underlying cell layer) 
were calculated and the results are shown as percentage of homocysteine in control 
medium. Panel E: Global DNA methylation. The percentage of methylated cytosine residues 
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is shown in medium containing 0, 10, 100 or 1000ng folic acid per ml either in the absence 
(FB) or presence of vitamins B6 and B12 (F). Panel F: Expression of the smooth muscle cell 
marker genes ACTA2, SM22 and MYH11 in response to F and FB media correlated to 
expression of the reference gene GAPDH. Results are shown as fold change of expression 
relative to cells in control medium (CON). Panel G: Expression of the smooth muscle cell 
marker genes ACTA2, SM22 and MYH11 in response to retinoic acid treatment in F and FB 
media relative to expression of the reference gene GAPDH. Results are shown as fold change 
of expression relative to untreated cells (i.e. in CON medium in the absence of retinoic acid). 
Measurements (n=4) were analysed by one-way ANOVA. p<0.05: *, p<0.01: **, p< 0,001: 
***.  
 
Figure 5. Differentiation of A7r5 rat smooth muscle cells. Panel A: Micrographs of A7r5 cells 
at exponential growth and 3 days after reaching confluence. Cells were photographed at a 
magnification of 40x. Scale bar: 100um. Panel B: Western blot analysis of protein extracts 
from growing and confluent cells using antisera directed against β-actin (ACTB) and smooth 
muscle α-actin (ACTA2). Extracts from HEK 293 cells (which do not express ACTA2) were 
used as negative control. Panel C: Abundance of ACTA2 protein relative to ACTB protein in 
proliferating and confluent A7r5 cells as quantified by densitometry. Panel D: Expression of 
smooth muscle specific genes SM22, smooth muscle α-actin (ACTA2), smooth muscle myosin 
heavy chain (MYH11), brain specific creatine kinase (CKB) and muscle specific creatine kinase 
(CKM) in A7r5 cells 3 days and 10 days after reaching confluence. Expression is shown as 
percentage of expression in proliferating cells. Statistical analysis (n=3) was done by ANOVA. 
p<0.05: *, p<0.01: **, p< 0,001: ***.  
 
Figure 6: Cellular responses to folate (F) and combined folate and B6 deficiency (FB) in A7r5 
cells grown in the respective media for 21 days. Panel A: Representative microscopy pictures 
of A7r5 cells grown in full medium (CON), folate deficient medium (F; containing a residual 
concentration of 0.6ng folate per ml derived from serum) and medium deficient in folate 
and vitamins B6 (pyridoxal) and B12. Cells were photographed at a magnification of 100x. 
Scale bar: 40um. Panel B: Impact of different medium folate concentrations (from 0 to 
100ng/ml) on cell growth over a period of 21 days (as determined by trypan blue staining at 
the end of the incubation period using a haemocytometer). Panel C: Growth of A7r5 cells in 
medium containing 10ng/ml of folate (10F), no folate (F), no folate and no vitamin B6 (FB), 
or control medium (CON; 100ng/ml of folate) over an 18-day period as determined by trypan 
blue staining at the indicated time points using a haemocytometer. Panel D: Cellular folate 
concentrations of cells grown in control or F or FB medium as measured by RIA. Panel E: 
Homocysteine concentration in medium of cells grown in control or F or FB medium 
(measured by LC-MS) expressed as nMol of homocysteine per μg of DNA (derived from the 
underlying cells). Panel F: Global DNA methylation as measured by LC-MS. Results are shown 
as percentage of methylation in CON medium. Panel G: Expression of the smooth muscle cell 
marker genes ACTA2, SM22 and MYH11 in response to F and FB medium correlated with 
expression of the reference gene GAPDH. Results are shown as fold change of expression 
relative to control cells. Panel H: Expression of Dnmt1 and Dnmt3a. Measurements (n=4) 
were analysed by one-way ANOVA. p<0.05: *, p<0.01: **, p< 0,001: ***.  
 
Supplementary Figure 3: Cellular responses to different combinations of folate and vitamin 
B6 content of cell culture medium. Folate concentrations were 4000ng/ml (F:4000), 10ng/ml 
(F:10) or 0ng/ml (F:0; equating to 0.6ng/ml when the residual folate in serum is taken into 
account). Pyridoxal/B6 concentrations were 23μM (B6: 23, 0.1μM and 0μM. Panel A: 
Homocysteine content of medium derived from A7r5 cells grown in different combinations 
of folate and vitamin B6 as measured by LC-MS expressed as nMol of homocysteine per μg 
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of DNA (derived from the underlying cells). Panel B:  Global DNA methylation as measured 
by LC-MS. Measurements (n=4) were analysed by one-way ANOVA. p<0.05: *, p<0.01: **, p< 
0,001: ***. 
 
Supplementary Figure 4: Cellular responses different combinations of folate and methionine 
content of cell culture medium. Folate concentrations were 4000ng/ml, 10ng/ml or 0ng/ml 
(equating to 0.6ng/ml when the residual folate in serum is taken into account). Methionine 
concentrations were 200μM, 20μM and 0μM. Panel A: Impact of different combinations of 
folate and methionine on cell growth over a period of 11 days. Panel B: Homocysteine 
content of medium derived from A7r5 cells grown in different combinations of folate and 
methionine as measured by LC-MS expressed as nMol of homocysteine per μg of DNA 
(derived from the underlying cells). Panel C: Cellular folate concentrations of cells as 
measured by RIA. Panel D: Global DNA methylation as measured by LC-MS. Panel E: 
Expression of the smooth muscle cell marker genes ACTA2, and MYH11 in response to F and 
FM (folate and methionine deficient) medium correlated to expression of the reference gene 
GAPDH. Results are shown as fold change of expression relative to control cells. 
Measurements (n=4) were analysed by one-way ANOVA. p<0.05: *, p<0.01: **, p< 0,001: 
***. 
 
Figure 7: Principal component analysis of a transcriptome analysis of A7r5 cells grown in 
medium containing 2.5ng/ml (shown in green), 10ng/ml (shown in orange) or 100ng/ml of 
folate (shown in red) for 7, 14 and 21 days. The first principal component separates the data 
by day of analysis; the second principal component separates the data by folate 
concentration. 
 
Figure 8: Venn diagrams of the genes changed during the different incubation periods and 
the different folate concentrations. Genes included were significant with a p-value < 0.001 
and a fold change of > 2. Note that very few gene changes are found at time points between 
cells grown in 2.5ng/ml and 10ng/ml. 
 
Figure 9: Fold change of expression for 6 exemplary genes, which are highly responsive to 
modulations of folate concentrations in medium. Thioredoxin interacting protein (TXNIP), 
insulin induced gene 1 (INSIG1) and isopentenyl diphosphate isomerase (IDI1) are highly 
expressed in 100ng/ml of folate but downregulated in response to folate deficiency (panels 
A-C). Prion protein dublet (PRND), skeletal muscle myosin heavy chain (MYH2) and skeletal 
muscle α-actin (ACTA1) are induced in response to low folate concentrations (i.e. 2.5ng/ml) 
(panels D-F). Measurements (n=5) were analysed by one-way ANOVA. p<0.05: *, p<0.01: **, 
p< 0,001: ***. 
 
Supplementary Figure 5: Pathway analysis using the Enrichr software suite. Panels A-C show 
the most significantly activated pathways detected using a list of genes activated >2 fold 
with a p-value <0.01 in response to low folate supply (2.5ng/ml vs. 100ng/ml folate at day 
21). Pathways detected in the NCI-Nature, OMIM disease and Reactome databases are 
shown. Panels D-F show the most significantly activated pathways detected using a list of 
genes activated >2 fold with a p-value <0.01 in response to high folate supply (100ng/ml vs. 
2.5ng/ml folate at day 21). Pathways detected in the NCI-Nature, WikiPathways and 
Reactome databases are shown. 
 
Figure 10: Panel A: Growth of A7r5 cells in medium containing 10%, 0.5% and 0.1% foetal 
calf serum over a period of 11 days. Panel B: Growth of A7r5 cells in control medium and 
medium containing 0.01μM of the iron chelator deferoxamine (DFO). Panel C: Expression of 
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the genes ID1, INSIG1, TXNIP1 and IDI1 which were found to be downregulated in response 
to folate deficiency. Gene expression was measured in cells grown in medium containing 
0.5% serum (FCS), 0.01μM DFO (FE) or 0.6ng/ml folate (F). Gene expression was correlated 
with expression of the reference gene β-actin. Results are shown as fold change of 
expression relative to control cells. Panel D: Expression of the genes MYH2, ACTA1, and 
PRND which were found to be upregulated in response to folate deficiency. In addition, 
expression of the Dnmt3a gene was measured. Measurements (n=3) were analysed by one-
way ANOVA. p<0.05: *, p<0.01: **, p< 0,001: ***. 
 
Supplementary Figure 6: Control substrates for methylation analyses. Panel A: Schematic 
representation of the approaches used to generate non-methylated and fully methylated 
genomic DNA. Panel B: Analysis of DNA methylation efficiency of the SssI DNA methyl 
transferase using bacteriophage lambda DNA as template. Note that untreated lambda DNA 
is fully digested by BstUI (yielding 25 fragments), whereas SssI treated DNA is fully protected 
against digestion. Panel C: Untreated (unmethylated) and SssI treated lambda DNA was 
mixed in 6 different ratios (containing 100%, 50%, 25%, 12.5%, 6.25% or 3.1% of SssI treated 
DNA) and cytosine methylation was measured by LC-MS. The amount of SssI treated DNA 
added and percentage of methyl-cytosine measured is correlated. Panel D: Global DNA 
methylation as measured by LC-MS for methylated cytosine. The percentage of methyl-
cytosine (% mC) is shown for DNA derived from A7r5 cells grown in control medium (CON), 
in medium supplemented with 10μM azacytidine, A7r5 DNA derived from whole genome 
amplification (WGA) or treatment with SssI (CON[+]) or DNA derived from whole genome 
amplification and subsequent SssI treatment (WGA[+]). Measurements (n=3) were analysed 
by one-way ANOVA. p<0.05: *, p<0.01: **, p< 0,001: ***. 
 
Supplementary Figure 7: Treatment of A7r5 cells with azacytidine. A7r5 cells were seeded 
into 6cm dishes (n=4) in normal medium. 24h later cells the medium was changed to 4 
different concentrations of azacytidine (0.1, 1, 5 or 10μM) or control medium. 72h later the 
medium was changed back to control medium. After a further 72h cells were counted and 
genomic DNA was isolated. Panel A: Cell counts after azacytidine treatment. Panel B: Global 
DNA methylation as measured by LC-MS. Data were analysed by ANOVA. Error bars indicate 
standard deviation. p<0.05: *, p<0.001: ***.  
 
Figure 11: COBRA analysis of DNA methylation at LINE1 (a repetitive mobile genetic element 
which serves as a proxy for global DNA methylation). Panel A: Schematic representation of 
the LINE1 section used for DNA amplification with the primer pair LINE-1s/as (from Pogribny 
et al. 2006). The location of the primer binding sites, the expected PCR product and its BstUI 
restriction digestion products are indicated, as are the CpG nucleotides in the amplified DNA 
region. A BstUI site (CGCG) is maintained in methylated but not in non-methylated DNA, 
where it is converted to TGTG. The rate of digestion is therefore reflective of the 
methylation rate of both CG dinucleotides (i.e. increases in digestion signify increases in 
methylation). Panel B: Polyacrylamide gel analysis of BstUI digested of LINE-1 PCR product. 
Different ratios of non-methylated (WGA: whole genome amplification) and untreated A7r5 
DNA were mixed prior to bisulfite conversion and PCR amplification (from 100:0 to 0:100). 
The PCR products were purified and digested with BstUI and separated on a 10% 
polyacrylamide gel alongside a molecular weight marker (NEB PCR marker). The sizes of the 
relevant DNA fragments are indicated. Panel C: Polyacrylamide gel with COBRA samples 
derived from A7r5 cells grown in control medium (100ng/ml folate: CON), medium 
containing 10ng/ml folate (10F), medium without added folate (0.6ng/ml: F), and medium 
containing no added folate or vitamin B6 (FB). Panel D: Quantification of DNA methylation 
after image analysis of the gel shown in panel B. The percentage of methylated input DNA is 
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correlated with DNA methylation measured by BstUI digestion. Panel E: Quantification of 
DNA methylation after image analysis of the gel shown in panel C. Panel F: Quantification of 
DNA methylation in A7r5 cells treated with folate deficient medium (F), iron deficient 
medium (FE) or medium with 0.5% FCS (FCS) as measured by COBRA analysis of the LINE1 
element. Measurements (n=3) were analysed by one-way ANOVA. p<0.05: *. 
 
Supplementary Figure 8: COBRA analysis of DNA methylation at LINE1. Panel A: Schematic 
representation of the LINE1 section used for DNA amplification with the primer pair LINE-
1s/as (from Pogribny et al. 2006; table 2). The location of the primer binding sites, the 
expected PCR product and its RsaI restriction digestion products are indicated, as are the 
CpG nucleotides in the amplified DNA region. The RsaI (recognition sequence GTAC) site is 
generated by bisulfite conversion of the original sequence GCACG to a GTACG, but only 
maintained if the CG dinucleotide at the end of the recognition site is maintained. Therefore, 
digestion of the RsaI site is reflective of an increase of methylation at this CG site. Panel B: 
Polyacrylamide gel analysis of RsaI digested of LINE-1 PCR product. Different ratios of non-
methylated (WGA: whole genome amplification) and untreated A7r5 DNA were mixed prior 
to bisulfite conversion and PCR amplification (from 100:0 to 0:100). The PCR products were 
purified and digested with RsaI and separated on a 10% polyacrylamide gel alongside a 
molecular weight marker (NEB PCR marker). The sizes of the relevant DNA fragments are 
indicated. Panel C: Polyacrylamide gel with COBRA samples derived from A7r5 cells grown in 
control medium (100ng/ml folate: CON), medium containing 10ng/ml folate (10F), medium 
without added folate (0.6ng/ml: F), and medium containing no added folate or vitamin B6 
(FB). Panel D: Quantification of DNA methylation after image analysis of the gel shown in 
panel C. The percentage of methylated input DNA is correlated with DNA methylation 
measured by RsaI digestion. Measurements (n=3) were analysed by one-way ANOVA. 
p<0.05: *. 
 
Supplementary Figure 9: COBRA analysis of DNA methylation at the first exon of the 
estrogen receptor alpha (ERa) gene. Panel A: Schematic representation of the ERa gene used 
for DNA amplification with the primer pair ERa-e1 s/as (from Monje et al. 2007, table 2) [34]. 
The location of the primer binding sites, the expected PCR product and its BstUI restriction 
digestion products are indicated, as are the CpG nucleotides in the amplified DNA region. 
Panel B: Polyacrylamide gel analysis of BstUI digested ERa PCR product. Different ratios of 
non-methylated (WGA: whole genome amplification) and untreated A7r5 DNA were mixed 
prior to bisulfite conversion and PCR amplification (from 100:0 to 0:100). The PCR products 
were purified and digested with BstUI and separated on a 10% polyacrylamide gel alongside 
a molecular weight marker (NEB PCR marker). The sizes of the relevant DNA fragments are 
indicated. Panel C: Polyacrylamide gel with COBRA samples derived from A7r5 cells grown in 
control medium (100ng/ml folate: CON), medium containing 10ng/ml folate (10F), medium 
without added folate (0.6ng/ml: F), and medium containing no added folate or vitamin B6 
(FB). Panel D: Quantification of DNA methylation after image analysis of the gel shown in 
panel C. The percentage of methylated input DNA is correlated with DNA methylation 
measured by BstUI digestion. Measurements (n=3) were analysed by one-way ANOVA. 
p<0.05: *. 
 
Supplementary Figure 10: DNA methylation and activity of the CMV promoter. Panel A: 
Fluorescent microscope picture of A404 cells stably transfected with the plasmid CMV-nGFP 
carrying a GFP gene linked to a nuclear localisation signal under the control of the CMV 
promoter. Panel B: Fluorescent microscope picture of HEK293 cells stably transfected with 
the plasmid CMV-nGFP. Panel C: Schematic representation of the CMV promoter region 
used for DNA amplification with the primer pair CMV-BSP-s and CMV-BSP-as. The location of 
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the primer binding sites, the expected PCR product and its SfaNI restriction digestion 
products are indicated. Panel D: Polyacrylamide gel analysis of SfaNI digested CMV PCR 
product. Different ratios of non-methylated (WGA: whole genome amplification) and 
untreated genomic DNA (derived from transfected HEK293 cells) were mixed prior to 
bisulfite conversion and PCR amplification (from 100:0 to 0:100). The PCR products were 
purified and digested with SfaNI and separated on a 10% polyacrylamide gel alongside a 
molecular weight marker (NEB PCR marker). The sizes of the relevant DNA fragments are 
indicated. Panel E: Polyacrylamide gel analysis of SfaNI digested CMV PCR product amplified 
from genomic DNA of 4 independent stable CMV-nGFP cell clones derived from HEK293 and 
A404 cells. 
 
Figure 12: COBRA analysis of DNA methylation at the rat PRND gene. Panel A: Schematic 
representation of the PRND gene section used for DNA amplification with the primer pair 
PP2-s and PP2-as. The location of the primer binding sites, the expected PCR product and its 
BstUI restriction digestion products are indicated, as are the CpG nucleotides in the 
amplified DNA region. Panel B: Polyacrylamide gel analysis of BstUI digested PRND PCR 
product amplified from A7r5 cells grown in control medium (100ng/ml folate: CON), folate 
deficient medium (F), iron deficient medium (FE) or medium with 0.5% FCS (FCS). The PCR 
products were purified and digested with BstUI and separated on a 10% polyacrylamide gel. 
The sizes of the relevant DNA fragments are indicated. Panel C: Quantification of DNA 
methylation after image analysis of the gel shown in panel B. The percentage of methylated 
input DNA is correlated with DNA methylation measured by BstUI digestion. Measurements 
(n=3) were analysed by one-way ANOVA. p<0.01: **. 
 
Supplementary Figure 11: Schematic representation of the MYH2, ACTA1, ID1, PRND, 
INSIG1, IDI1 and TXNIP genes regulated by folate supply in A7r5 cells. The mRNA, coding 
sequences (CDS), the predicted CpG islands and the regions used for pyrosequencing 
analysis are indicated. 
 
Figure 13: Pyrosequencing analysis of CpG islands of the ACTA1 (panel A), MYH2 (panel B), 
INSIG1 (panel C), TXNIP (panel D), ID1 (panel E), IDI1 (panel F) and PRND genes (panels G 
and H). Genomic DNA was derived from A7r5 cells grown in low serum (0.5% FCS; indicated 
as FCS), iron deficiency (10μM DFO; indicated as FE) or folate deficiency (0.6nM folate; 
indicated as F). The percentage of methylated Cs at each of the polymorphism positions is 
indicated. Panel G: Quality control of the pyrosequencing analysis for the Prnd gene. 
Different ratios of non-methylated (WGA: whole genome amplification) and untreated A7r5 
DNA were mixed prior to bisulfite conversion and PCR amplification (from 100:0 to 0:100) 
before being analysed by pyrosequencing at the Prnd gene. Data are the average of 3 
independent replicates and were analysed by ANOVA. p < 0.05: *. 
 
Supplementary Figure 12: Pyrosequencing analysis of CpG rich regions of the MYH2 (panel 
A), PRND (panel B), TXNIP (panel C), and IDI1 (panel D) genes. Genomic DNA was derived 
from A7r5 cells grown in folate and vitamin B6 deficient medium (FB) or 10mM azacytidine 
(as outlined in suppl. Fig. 7; AZA). The percentage of methylated Cs at each of the 
polymorphism positions is indicated. Data are the average of 3 independent replicates and 
were analysed by ANOVA. p < 0.05: *, p < 0.01: **, p < 0.001: ***. 
 
Table 1: Oligonucleotides used for quantitative PCR. Primer sequences, annealing temperatures and 




name primer sequence annealing  product  Genbank 
rat MYH11 rsmMYH3 CTGGGGAGCTGCGTGTC  57.4°C 530bp NM_001170600.1 
 
rsmMYH4 AGCGGCCTTCTCCTCATACTG  
   rat CKB rbCK1 AGAAAGGGGGCAACATGAAGGAAG  58.3°C 482bp NM_012529.3 
 
rbCK2 GCACTGCCCGGGTAATAAG  
   rat CKM rmCK1 GCGTGGGCCTGCAGAAGATTGA  62.9°C 441bp NM_012530.2 
 
rmCK2 TCCAGGGGGCGGGGCTCCAG  
   rat TAGLN rSM22-1 ATGGCGTGATTCTGAGCAAGTT  57°C 415bp NM_031549.2 
 
rSM22-2 GGTCGCCCATAGCCTGTC  
   rat ACTA2 rsm-a-actin1 CTGGCCGAGATCTCACCGACTACC  59.6°C 490bp NM_031004.2 
 
rsm-a-actin2 GAGCCGCCGATCCAGACAGAATA  
   rat GAPDH rGAPDH3 GCTTTCCAGAGGGGCCATCCACA  59°C 426bp NM_017008.4 
 
rGAPDH4 ACGGCAAGTTCAACGGCACAGTCA  
   rat DNMT1 rDnmt1-3 GTGCCTGCCAGCTGAGTGTTGTG  60°C 483bp NM_053354.3 
 
rDnmt1-4 ACCAGGGGATGAGCGTGTTGAAT  
   rat DNMT3a rDnmt3a-1 GCACGGGCCGCCTCTTCTT  60°C 502bp NM_001003957.1 
 
rDnmt3a-2 CACGATCGGCCCAGCAGTCTCT  
   rat DNMT3b rDnmt3b-1 AGCCAGGAGACGCGAGAACAAAAG  60°C 412bp NM_001003959.1 
 
rDnmt3b-2 ACCCACCAGCACCTCCAGACACTC  
   rat INSIG1 rInsig1-1 TCTCCTCCGCCTGGTGGGTG 60°C 268bp NM_022392.1 
 
rInsig1-2 CCCAGGCCACTTCGGGATCG 
   rat IDI1 rIDI1-1 GTTGAAGTACGGCGCTCCGCA 60°C 418bp NM_053539.1 
 
rIDI1-2 AGCGCTTCTGTGCTGCTCGTTT 
   rat LUM rLum1 GCCCGCTGGCCTTCCAACAT 55°C 350bp NM_031050.1 
 
rLum2 GGGGATTGCCATCCAAGCGCA 
   rat ID1 rIDB1 TGTCGGAGCAAAGCGTTGCCA 61.5°C 331bp NM_012797.2 
 
rIDB2 GCTGGAACACATGCCGCCTCGG 
   rat PRND rPPD1 ACCGAAGCCCAGGTGGCTGA 60°C 373bp NM_001102431.1 
 
rPPD2 CCAGCAGGCAGACCATCGCC 
   rat ACTA1 rACTA1-1 GGCAATGAGCGCTTCCGTTGC 59°C 392bp NM_019212.2 
 
rACTA1-2 AGACGCGGGTGCGCCTAGAAG 
   rat MYH2 rMYH2-1 TGGAGGCCAGAGTGCGTGAAC 55°C 436bp NM_001135157.1 
 
rMYH2-2 CACATGGGGACATGACCAAAGGC 
   rat TXNIP rTIP-1 AGTGGGTACACCCCCGCCTC 55°C 300bp NM_001008767.1 
 
rTIP-2 TGGCTCTGTTGCCCCATGGC 
   mm DNMT1 mDnmt1-1 GGTGGATGGCCGGGTCTACTGC  60°C 489bp NM_001199431.1 
 
mDnmt1-2 GGGCCCCCTTGTGAATAATCCT  
   mm DNMT3a mDnmt3a-1 CACCTATGGGCTGCTGCGAAGAC  60°C 419bp NM_007872.4 
 
mDnmt3a-2 GGCGGCCAGTACCCTCATAAAGT  
   mm DNMT3b mDnmt3b-1 TGTCGGAGCAAAGCGTTGCCA 60°C 414bp NM_001003961.4  
 
mDnmt3b-2 TGGCAGCGCTGAGGGAGGCACATA  
   mm Oct4 mOct4-1 ACCGCCCCAATGCCGTGAAGTT  60°C 593bp NM_013633.3 
 
mOct4-2 TGGGGGCAGAGGAAAGGATACAGC  
   mm ACTA2 mACTA2 AGTCGCTGTCAGGAACCCTGAGACG 57°C 296bp NM_007392.3 
 
mACTA2 ATCTTTTCCATGTCGTCCCAGTTG 
   mm MYH11 mMYH11-1 AGGAAACACCAAGGTCAAGCA  57°C 324bp NM_013607.2  
 
mMYH11-2 CCCTGACATGGTGTCCAATC 
   mm SM22 mSM22a-1  TCCAGTCCACAAACGACCAAGC 57°C 328bp NM_011526.5 
 
mSM22a-2 GAATTGAGCCACCTGTTCCATCTG 
    




name primer sequence annealing  product  Genbank 




(Pogribny et al. 06) 




(Monje et al. 07) 




(Chen et al. 10) 
rat PRND rPP2-s TTATTGGTAGTTTTTTGATGGGA 59°C 283bp NM_001102431.1 
 
rPP2-as AAACCAAATAAAACCCAACAAA 
   CMV CMV-BSP-s TGATTTTATGGGATTTTTTTATTT 52°C 269bp X17403.1 
 
CMV-BSP-as CAACTCTACTTATATAAACCTCCCA 
    




name sequence annealing  product  










GATGAYGYGT TTGGTATGGG YGGAGATTAG GGGYGGGGGG 
AATTYGTAGG [+2554 to +2700 from transcriptional start] 










ATTTATTTTT AYGAGTTYGT TGTGTTGTAT AATTTTAAAG 
AGYGTTAYGT AGTTTGGATG ATTTAYGT [+2379 to +2502 
from transcriptional start] 










GGTGATTYGT TGYGTTAAYG TTATTTAGGY GGTTAATTAG 
GTTGAGTTTT TTYGGGAGAA [+311 to +405 from 
transcriptional start] 










GGTGGTYGGT YGGGTGATAG TGGAAGTGTG TGAAGTTATT 





YGGAATGTTAYGTTTTTTTYGGAYGA [PM00547638] [+308 to 









TTYGTAYGTTTAGTTGTTTTGYGGT [PM00504119] [-65 to -23 






Table 4: Top 20 gene expression changes in response to folate deficiency. Fold change of gene 
expression between A7r5 cells grown in in folate sufficient (100ng/ml) and folate deficient (2.5ng/ml) 
medium 
 
name gene description fold change Genbank 
    
 
expression increased in 100ng/ml vs 2.5ng/ml folate 
  Txnip  thioredoxin interacting protein 8.97 U30789 
Itgb8 integrin subunit beta 8, transcript variant X1 8.61 XM_006240697.3 
Lum  lumican 8.34 NM_031050 
Insig1  insulin induced gene 1 8.10 NM_022392 
Idi1  isopentenyl-diphosphate delta isomerase 6.55 NM_053539 
Ednra  endothelin receptor type A 6.04 BF414702 
Ptn  pleiotrophin 5.99 NM_017066 
Itgb8 integrin subunit beta 8, transcript variant X1 5.97 XM_006240697.3 
Scd2  stearoyl-Coenzyme A desaturase 2 5.84 NM_031841 
Cdc20  cell division cycle 20 homolog 5.44 U05341 
Idi1  isopentenyl-diphosphate delta isomerase 4.61 BI290053 
LOC684841  histone H3.2-like 4.48 XM_006222398.2 
Slc29a1  solute carrier family 29 (nucleoside transporters), member 1 4.46 NM_031684 
Cenpw centromere protein W 4.41 NM_001246319.1 
Kif20a  kinesin family member 20A 4.38 BE111697 
Cdca3  cell division cycle associated 3 4.34 BF417638 
Nrp1  neuropilin 1 4.21 AF016296 
Arrdc4 arrestin domain containing 4 4.18 XM_006229367.3 
Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 3.93 NM_017268 
Kif11 kinesin family member 11 3.93 BE116384 
    
 
expression increased in 2.5ng/ml vs 100ng/ml folate 
  Prnd  prion protein dublet 24.95 BF551984 
Myh2  myosin, heavy polypeptide 2, skeletal muscle, adult 11.52 BI277586 
Id1  inhibitor of DNA binding 1 9.79 M86708 
Acta1  actin, alpha 1, skeletal muscle 9.11 NM_019212 
F3  coagulation factor III 9.10 NM_013057 
Tnnt1  troponin T1, skeletal, slow 8.92 AF399874 
Plcxd2 phosphatidylinositol-specific phospholipase C 7.81 NM_001134481.1 
Myh3  myosin, heavy polypeptide 3, skeletal muscle, embryonic 7.38 NM_012604 
Id2 inhibitor of DNA binding 2 6.96 BC086391.1 
Scg2  secretogranin II 6.73 NM_022669 
Vsnl1  visinin-like 1 6.51 AI227991 
Rnf181  ring finger protein 181 6.31 AI008549 
Tnc  tenascin C 6.31 AI176034 
Isg12(b)  putative ISG12(b) protein 6.13 AA819034 
Prss35  protease, serine, 35 5.88 AA866443 
Myl2  myosin, light polypeptide 2, regulatory, cardiac, slow 5.38 BF419995 
Trib3  tribbles homolog 3 5.37 AB020967 
Pcp4 Purkinje cell protein 4 5.10 NM_013002 
Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A 5.00 NM_022676 




Table 5: TOP-GO pathway analysis of transcriptome changes in response to folate deficiency. elimKS 
here gives the p-values from topGO specific Kolmogorov-Smirnov Test with elimination of genes of 
significant GO-terms in parent terms. 
 
 
GO.ID Term Annotated Significant Expected elimKS 
GO:0007076 mitotic chromosome condensation 17 16 5.02 3.40E-07 
GO:0006695 cholesterol biosynthetic process 65 38 19.18 1.30E-06 
GO:0051301 cell division 621 249 183.24 1.40E-06 
GO:0000381 regulation of alternative mRNA splicing 80 43 23.61 2.20E-06 
GO:0070507 regulation of microtubule cytoskeleton 288 104 84.98 6.10E-06 
GO:0007059 chromosome segregation 412 188 121.57 1.10E-05 
GO:0034508 centromere complex assembly 31 19 9.15 1.70E-05 
GO:0031055 chromatin remodelling at centromere 14 12 4.13 1.70E-05 
GO:0045214 sarcomere organization 87 45 25.67 1.90E-05 
GO:0071897 DNA biosynthetic process 215 98 63.44 2.00E-05 
 
 
 
 




























